Le Lézard
Classified in: Health
Subjects: NPT, PDT

Cure Alzheimer's Fund PSA Focused on the Impact of Alzheimer's Disease Playing in More than 1,200 Movie Theaters Nationwide


WELLESLEY, Mass., April 20, 2018 /PRNewswire/ -- A new public service announcement (PSA) created by BBDO New York on behalf of Cure Alzheimer's Fund has been released and is now playing in over 1200 movie theaters nationwide. The 2 minute film directed by David Shane of O Positive Films, titled "Daughter and Mother," shows the daily impact of Alzheimer's disease.

Cure Alzheimer's Fund

David Lubars, Global Chief Creative Officer for BBDO and a private donor to Cure Alzheimer's Fund, lost his mother to Alzheimer's disease in 2013. The film shows the particular hardships of the disease experienced by women.

"This film highlights a few difficult truths about Alzheimer's disease ? how it disproportionately affects women, both as individuals suffering with the disease and as caregivers, and its long-term impact," said Barbara Chambers, Senior Engagement Officer of Cure Alzheimer's Fund.  "BBDO is well known for its creativity and sensitivity and we are so grateful for all of their talent and work in producing this film."

Studies show that women develop Alzheimer's disease at twice the rate of men, and by the age of 75 a woman is three times more likely to have Alzheimer's than a man. In 2017, Cure Alzheimer's Fund launched a new website ? WomenandAlzheimers.org - committed to providing women with information dedicated to their struggle with this devastating illness.  Additionally, the Wellesley-based organization is funding major research projects focused on the relationship between women and Alzheimer's disease.

The PSA is playing through April 26th on more than 16,000 movie screens in over 200 markets including the major metropolitan areas of Atlanta, Boston, Chicago, Dallas, Los Angeles, Philadelphia, New York, San Francisco, Seattle and Washington, DC. The film will continue to run in theater lobbies through May 31st.

The "Daughter and Mother" PSA was recently awarded a Silver Hugo award at the Chicago International Film Festival and was named AdWeek's Ad of the Day on March 26th

In 2017, Cure Alzheimer's Fund distributed $15.7 million in research grants to scientists around the world. The non-profit saw growth in research spending last year, both in terms of the research dollars expended and number of projects funded. A total of 67 projects were distributed throughout the year. Since its founding in 2004, Cure Alzheimer's Fund has surpassed $67 million in research spending and funded more than 300 projects.

Alzheimer's is the sixth leading cause of death in the US and is the country's most expensive disease, with care for it and other forms of dementia costing more than $250 billion this year. There are currently 6 million people in the U.S. with Alzheimer's and nearly 50 million worldwide, and this is expected to triple in the next 30 years.

For more information on Cure Alzheimer's Fund, please visit https://www.curealz.org/.

About Cure Alzheimer's Fund

Cure Alzheimer's Fund is a non-profit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer's disease. Since its founding in 2004, Cure Alzheimer's Fund has contributed over $67 million to research, and its funded initiatives have been responsible for several key breakthroughs ? including the groundbreaking "Alzheimer's in a Dish" study. Cure Alzheimer's Fund has received a four star rating from Charity Navigator seven consecutive times. With 100 percent of funds raised going directly to research, Cure Alzheimer's Fund has been able to support some of the best scientific minds in the field of Alzheimer's research. For more information, please visit https://www.curealz.org/

MEDIA CONTACT
Suzanne Morse
[email protected]
617-646-1020

 

SOURCE Cure Alzheimer's Fund


These press releases may also interest you

at 07:15
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") , InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise...

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...



News published on and distributed by: